Doug Godfrin, PhD - VeraMorph

<p><a href= "https://syndicate.angelinvestboston.com/en-us/the-surge-of-opportunities-in-angel-scale-biotech"> Why Sal Is Bullish on Biotech</a></p> <p>VeraMorph has a new way to deliver insoluble drugs by mouth. Founder Doug Godfrin, PhD elucidates the promise of accessing the 85% of drugs that are not soluble. Does VeraMorph pass Sal Daher’s screen for angel-scale biotech? Listen and find out.</p> <p>Sponsors: Purdue University entrepreneurship and Peter Fasse, patent attorney at Fish and Richardson</p> <p>Highlights:</p> <ul> <li>Sal Daher, CFA Introduces Doug Godfrin, PhD, Founder of VeraMorph</li> <li>A New Way to Deliver Drugs Orally</li> <li>How VeraMorph Gets Around the Solubility Problem</li> <li>VeraMorph’s Approach Is Janus-like: Shelf Stable but Available Where Needed</li> <li>The Decade of Biotech & VeraMorph</li> <li>AltrixBio: Gastric Bypass Surgery in a Pill</li> <li>Sal Daher’s Biotech Screen: Strong Patents</li> <li>“VeraMorph actually owns the patents outright for this platform technology.”</li> <li>“We've really taken a totally different perspective with this class of material by focusing on immediate release via oral delivery...”</li> <li>Sal Daher’s Biotech Screen: Capable Academic Founder</li> <li>Sal Daher’s Biotech Screen: Is it Angel-Scale?</li> <li>US$1 Million Will Get VeraMorph to Production for Pre-Clinical Trials</li> <li>“...chances of reaching that next set of milestones is 90% or above.”</li> <li>Doug Godfrin Is Collaborating with Colin Minchom, PhD, a Veteran of Drug Development</li> <li>US$ 2 to 3 million More Will Take VeraMorph to Clinical Stage, Doug Predicts</li> <li>Sal and Doug Look at the Odds of Getting to Clinical Stage</li> <li>Sal Daher’s Biotech Screen: Do Strategics Care?</li> <li>Sal Daher’s Biotech Screen: Platform Technology?</li> <li>Sponsors Purdue University and Peter Fasse Are Founder-Friendly</li> <li>The Upside of Failure in Biotech</li> <li>This guy calls me up, "Saleh, let's get together at Darwin's in Cambridge. I want to talk to you about a new company